Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 2, 2008, Pages 153-159

  Lloyd, A ^a   Penson, D ^b   Dewilde, S ^a   Kleinman, L ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG PREFERENCE; GYNECOMASTIA; HEALTH CARE COST; HEALTH SURVEY; HEMATURIA; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; PATIENT ATTITUDE; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CHOICE BEHAVIOR; CROSS-SECTIONAL STUDIES; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY; ERECTILE DYSFUNCTION; FLUTAMIDE; GYNECOMASTIA; HEALTH SURVEYS; HEMATURIA; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NITRILES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 43549119112     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500992     Document Type: Article

References (14)

1. Schelhammer PF, Sharifi R, Block N, Soloway MS, Venner PM, Patterson AL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advance prostatic carcinoma: Final repot of a double blind randomized multicenter trial. Urology 1997; 50: 330-336.
2. Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother 2002; 3: 1313-1328.
3. Jenkins V, Fallowfield L, Edginton T, Payne H, Hamilton E. Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Curr Med Res Opinion 2005; 21 1329-1335.
4. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004; 328: 382.
5. Louviere J, Hensher D, Swait JD, Adamowicz W. Stated Choice Methods: Analysis and Applications. Cambridge University Press: Cambridge, UK, 2000.
6. Ryan M, Farrar S. Using conjoint analysis to elicit preferences in health care. BMJ 2000; 320: 1530-1533.
7. Osman LM, McKenzie L, Cairns J, Friend JAR, Godden DJ, Legge JS et al Patient weighting of importance of asthma symptoms. Thorax 2001; 56: 138-142.
8. Lloyd A, McIntosh E, Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: A discrete choice experiment. Pharmacoeconomics 2005; 23: 1167-1181.
9. Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL, Newling D et al. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998; 33: 144-151.
10. Hedlund PO. Side effects of endocrine treatment and their mechanisms: castration, antiandrogens and estrogens. Prostate 2000; 10: 32-37.
11. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of randomised trials. Lancet 2000; 355: 1491-1498.
12. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
13. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F et al., for the International Prostate Cancer Study Group. Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Cancer 1993; 72: 3878-3879.
14. Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F et al Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer: The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993; 29A: 1088-1093.